Stock ADMA ADMA BIOLOGICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages ADMA Biologics, Inc.

Equities

ADMA

US0008991046

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
9.55 USD +0.74% Intraday chart for ADMA Biologics, Inc. -0.10% +111.28%
May. 10 HC Wainwright Adjusts ADMA Biologics' Price Target to $10 From $7.50, Maintains Buy Rating MT
May. 10 Cantor Fitzgerald Adjusts ADMA Biologics' Price Target to $10 From $8, Maintains Overweight Rating MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Glancy Prongay & Murray LLP Announces the Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Adamas Pharmaceuticals, Inc. - ADMS
HC Wainwright Adjusts ADMA Biologics' Price Target to $10 From $7.50, Maintains Buy Rating
Cantor Fitzgerald Adjusts ADMA Biologics' Price Target to $10 From $8, Maintains Overweight Rating
ADMA Biologics Shares Rise After Company Swings to Q1 Earnings, Lifts 2024 Guidance
ADMA Biologics Swings to Q1 Earnings, Revenue Rises; Lifts 2024 Guidance
Adma Biologics: Q1 Earnings Snapshot
ADMA Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Earnings Flash (ADMA) ADMA BIOLOGICS Posts Q1 Revenue $81.9M, vs. Street Est of $77.3M
ADMA Biologics, Inc. Revises Earnings Guidance for the Full Year 2024 and 2025
Transcript : ADMA Biologics, Inc., Q1 2024 Earnings Call, May 09, 2024
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
ADMA Biologics, Inc. Announces Promotion of Kaitlin Kestenberg as Chief Operating Officer
HC Wainwright Adjusts ADMA Biologics Price Target to $7.50 From $6, Maintains Buy Rating
Adma Biologics Insider Sold Shares Worth $2,803,741, According to a Recent SEC Filing
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
Adma Biologics, Inc. Announces FDA Approvals of Extended Room Temperature Storage Conditions for Asceniv & Bivigam
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
Mizuho Adjusts Price Target on ADMA Biologics to $10 From $9, Maintains Buy Rating
ADMA Biologics Q4 Net Loss Widens, Revenue Rises; Increases 2024, 2025 Revenue Outlook; Seeks Successor for Chief Financial Officer
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ADMA Stock
  4. News ADMA Biologics, Inc.
  5. Other languages